FAP, CD10, and GPR77-labeled CAFs cause neoadjuvant chemotherapy resistance by inducing EMT and CSC in gastric cancer

Zhao, Zehua; Zhu, Yanmei

doi:10.1186/s12885-023-11011-0

Table 2 The relationships between CAF, EMT, CSC biomarkers and clinicopathological characteristics

From: FAP, CD10, and GPR77-labeled CAFs cause neoadjuvant chemotherapy resistance by inducing EMT and CSC in gastric cancer

	FAP		P	χ²	CD10		P	χ²	GPR77		P	χ²	N-cadherin		P	χ²
	-	+	P	χ²	-	+	P	χ²	-	+	P	χ²	-	+	P	χ²
Gender			0.140	2.180			0.716	0.132			0.221	1.500			0.260	1.270
Male	73	55			104	24			110	18			77	51
Female	30	13			36	7			40	3			30	13
Age (yr)			0.793	0.069			0.228	1.451			0.417	0.660			0.327	0.959
<65	82	53			113	22			117	18			87	48
≥65	21	15			27	9			33	3			20	16
Tumor location			0.725	1.319			0.339	3.363			0.255	4.057			0.930	0.449
Lower third	51	38			74	15			74	15			55	34
Middle third	27	14			35	6			39	2			25	16
UGEJ	18	13			22	9			28	3			21	10
Diffuse	7	3			9	1			9	1			6	4
Tumour size (cm)			0.002	10.049			0.006	7.695			0.152	2.049			0.159	1.985
<5	49	16			60	5			60	5			45	20
≥ 5	54	52			80	26			90	16			62	44
ypT Stage			<0.001	21.699			0.016	5.753			0.035	4.428			0.004	8.185
0–2	36	3			37	2			38	1			32	7
3–4	67	65			103	29			112	20			75	57
ypN Stage			0.001	16.972			0.034	8.689			0.118	5.872			0.032	8.834
0	49	14			57	6			60	3			46	17
1	20	11			26	5			26	5			20	11
2	14	15			19	10			23	6			19	10
3	20	28			38	10			41	7			46	17
ypTNM Stage			<0.001	24.251			0.003	11.832			0.014	8.543			0.009	9.376
I	30	2			30	2			31	1			26	6
II	29	14			40	3			41	2			30	13
III	44	52			70	26			78	18			51	45
Histological types			0.961	0.002			0.255	1.296			0.333	0.938			0.666	0.187
Non-low-adhesion adenocarcinoman	64	42			84	22			95	11			65	41
Low-adhesion adenocarcinoma	39	26			56	9			55	10			42	23
Lauren classification			0.150	2.077			0.006	7.441			0.618	0.249			0.827	0.048
Intestinal	49	40			66	23			77	12			55	34
Diffuse or Mixed	54	28			74	8			73	9			52	30
Degree of differentiation			0.031	4.671			0.116	2.476			0.064	3.436			0.774	0.082
Well	26	8			31	3			33	1			22	12
Moderate or Poor	77	60			109	28			117	20			85	52
Vascular or lymphatic invasion			0.016	5.843			0.327	0.959			0.075	3.178			0.200	1.643
No	86	46			106	26			119	13			86	46
Yes	17	22			34	5			31	8			21	18
Nerve invasion			0.029	4.746			0.219	1.513			0.367	0.814			0.172	1.868
No	87	48			108	27			120	15			88	47
Yes	16	20			32	4			30	6			19	17
Mandard TRG			<0.001	43.852			<0.001	15.914			0.003	9.080			0.004	8.447
1–2	55	3			57	1			57	1			45	13
3–5	48	65			83	30			93	20			62	51

	Snail1		P	χ²	Twist1		P	χ²	ALDH1		P	χ²	LGR5		P	χ²	CD44		P	χ²
	-	+	P	χ²	-	+	P	χ²	-	+	P	χ²	-	+	P	χ²	-	+	P	χ²
Gender			0.092	2.838			0.624	0.241			0.086	2.941			0.301	1.068			0.760	0.094
Male	87	41			71	57			41	87			51	77			68	60
Female	35	8			22	21			20	23			21	22			24	19
Age (yr)			0.337	0.923			0.874	0.025			0.951	0.004			0.484	0.490			0.539	0.377
<65	94	41			73	62			48	87			55	80			71	64
≥65	28	8			20	16			13	23			17	19			21	15
Tumor location			0.906	0.559			0.657	1.612			0.258	4.028			0.226	4.349			0.876	0.690
Lower third	62	27			49	40			37	52			43	46			50	39
Middle third	30	11			21	20			13	28			15	26			20	21
UGEJ	22	9			19	12			7	24			9	22			17	14
Diffuse	8	2			4	6			4	6			5	5			5	5
Tumour size (cm)			0.360	0.837			0.002	9.315			0.789	0.071			0.840	0.041			0.112	2.526
<5	49	16			45	20			24	41			28	37			40	25
≥ 5	73	33			48	58			37	69			44	62			52	54
ypT Stage			0.037	4.352			<0.001	25.461			0.240	1.380			0.039	4.241			0.067	3.364
0–2	33	6			35	4			17	22			22	17			26	13
3–4	89	43			58	74			44	88			50	82			66	66
ypN Stage			0.606	1.842			0.060	7.399			0.203	4.601			0.986	0.147			0.382	3.066
0	48	15			42	21			27	36			26	37			32	31
1	23	8			17	14			13	18			14	17			21	10
2	19	10			14	15			9	20			12	17			14	15
3	32	16			20	28			12	36			20	28			25	23
ypTNM Stage			0.193	3.294			<0.001	23.236			0.194	3.279			0.198	3.243			0.307	2.360
I	27	5			29	3			15	17			18	14			21	11
II	29	14			24	19			17	26			17	26			23	20
III	66	30			40	56			29	67			37	59			48	48
Histological types			0.107	2.598			0.669	0.183			0.551	0.355			0.906	0.014			0.745	0.106
Non-low-adhesion adenocarcinoman	71	35			59	47			36	70			45	61			56	50
Low-adhesion adenocarcinoma	51	14			34	31			25	40			27	38			36	29
Lauren classification			0.011	6.442			0.460	0.546			0.576	0.312			0.443	0.588			0.035	4.466
Intestinal	56	33			46	43			30	59			35	54			41	48
Diffuse or Mixed	66	16			47	35			31	51			37	45			51	31
Degree of differentiation			0.753	0.099			0.034	4.491			0.251	1.319			0.009	6.729			0.512	0.431
Well	25	9			24	10			15	19			21	13			20	14
Moderate or Poor	97	40			69	68			46	91			51	86			72	65
Vascular or lymphatic invasion			0.462	0.541			0.419	0.654			0.137	2.216			0.103	2.663			0.276	1.189
No	96	36			74	58			51	81			60	72			74	58
Yes	26	13			19	20			10	29			12	27			18	21
Nerve invasion			0.777	0.081			0.827	0.048			0.650	0.206			0.660	0.194			0.539	0.377
No	97	38			74	61			47	88			58	77			71	64
Yes	25	11			19	17			14	22			14	22			21	15
Mandard TRG			0.006	7.410			<0.001	35.825			0.033	4.527			0.002	9.821			0.012	6.379
1–2	49	9			50	8			27	31			34	24			39	19
3–5	73	40			43	70			34	79			38	75			53	60

UGEJ Upper third and gastroesophageal junction

Back to article page

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com

BMC Cancer

Contact us